Science boffin students make prestigious ranking with revolutionary antibiotic therapy device

The prototype of the point-of-care diagnostic machine. It is 40 cm x 40 cm x 20 cm, it could analyze the smear of 6 patients at the same time. (that one on the pic is made for 2 patients). Biolumo

Polish students have made it into the Top 100 in the Journal of mHealth for designing a device that is set to revolutionise antibiotic therapy.

Olga Grudniak, 21, and Marcin Pitek, 21, third-year students of Biotechnology at the University of Gdańsk, came up with the idea after one of their tutors asked them if they could find a way to see if his son who had a bacterial infection had been given the right antibiotic. 

The answer they came up with is a point-of-care diagnostic tool designed for precision prescriptions. 

Jakub Wysocki, Chief Marketing Officer for the Biolumo company set up by the students, told TFN: “The whole idea is to give General Practitioners a tool to quickly select the targeted therapy individually for each patient without the need of a laboratory, which can be used by a nurse.”

The patient’s smear is first taken and then put into the device where different antibiotics have been placed. A short analysis shows which antibiotic can deal with the bacteria best.Biolumo

The tool combines software, hardware, and biotechnology to provide antibiogram test results and is adjusted to be used at the clinic or even a private office. 

A smear sample is placed into the machine which then analysis it before coming up with the correct antibiotic. 

Wysocki continued: “It is 12 times faster, automated and therefore easy to use in the clinic, not necessarily a laboratory, and affordable enough for healthcare - meaning the test will not cost more than an antibiogram. 

Science student Olga Grudniak, 21, is one of the two brains behind the revolutionary device. Biolumo

“We have designed a whole solution having mass usage in mind, in contrast to some of our competition.”

Though the tool hasn’t been certified yet, it is already on the prestigious list of Global Digital Health 100 and with several test runs under its belt, it is about to begin clinical validation and certification. 

The device, which has yet to be named, is set to enter the marketplace in two years.